LIVN Key Statistics, Chart & Performance
The current stock price of LIVN is 60.46 USD. In the past month the price increased by 11.39%. In the past year, price increased by 15.16%.
LIVN Latest News, Press Relases and Analysis
LIVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.49 | 221.37B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.03 | 203.79B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.23 | 145.27B | ||
| SYK | STRYKER CORP | 28.11 | 141.54B | ||
| IDXX | IDEXX LABORATORIES INC | 59.65 | 60.17B | ||
| BDX | BECTON DICKINSON AND CO | 13.24 | 54.73B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.96 | 49.16B | ||
| RMD | RESMED INC | 25.31 | 36.56B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.05 | 35.64B | ||
| DXCM | DEXCOM INC | 33.45 | 24.40B | ||
| PODD | INSULET CORP | 73.86 | 23.75B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.56 | 18.53B |
Related stock screener links
About LIVN
Company Profile
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Company Info
LIVANOVA PLC
20 Eastbourne Terrace
London W2 6LG GB
CEO: Damien McDonald
Employees: 2900
Phone: 442033250662
LIVANOVA PLC / LIVN FAQ
Can you describe the business of LIVANOVA PLC?
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
What is the current price of LIVN stock?
The current stock price of LIVN is 60.46 USD. The price increased by 9.35% in the last trading session.
Does LIVANOVA PLC pay dividends?
LIVN does not pay a dividend.
What is the ChartMill rating of LIVANOVA PLC stock?
LIVN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the growth outlook for LIVANOVA PLC?
The Revenue of LIVANOVA PLC (LIVN) is expected to grow by 8.58% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of LIVN stock?
LIVANOVA PLC (LIVN) has a market capitalization of 3.30B USD. This makes LIVN a Mid Cap stock.
Can you provide the upcoming earnings date for LIVANOVA PLC?
LIVANOVA PLC (LIVN) will report earnings on 2026-02-23, after the market close.
LIVN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LIVN. When comparing the yearly performance of all stocks, LIVN is one of the better performing stocks in the market, outperforming 79.83% of all stocks.
LIVN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to LIVN. LIVN has an average financial health and profitability rating.
LIVN Financial Highlights
Over the last trailing twelve months LIVN reported a non-GAAP Earnings per Share(EPS) of 3.85. The EPS increased by 12.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.5% | ||
| ROE | -18.79% | ||
| Debt/Equity | 0.3 |
LIVN Forecast & Estimates
16 analysts have analysed LIVN and the average price target is 68.98 USD. This implies a price increase of 14.1% is expected in the next year compared to the current price of 60.46.
For the next year, analysts expect an EPS growth of 13.5% and a revenue growth 8.58% for LIVN